1. Home
  2. NBB vs IVVD Comparison

NBB vs IVVD Comparison

Compare NBB & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

HOLD

Current Price

$15.69

Market Cap

465.9M

Sector

Finance

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.21

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBB
IVVD
Founded
N/A
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.9M
437.1M
IPO Year
2010
2021

Fundamental Metrics

Financial Performance
Metric
NBB
IVVD
Price
$15.69
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.75
AVG Volume (30 Days)
44.6K
1.9M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$61.57
Revenue Next Year
N/A
$41.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$14.95
$0.49
52 Week High
$16.62
$3.07

Technical Indicators

Market Signals
Indicator
NBB
IVVD
Relative Strength Index (RSI) 43.19 35.96
Support Level $15.55 $1.11
Resistance Level $16.05 $1.41
Average True Range (ATR) 0.22 0.12
MACD -0.00 -0.02
Stochastic Oscillator 23.26 19.35

Price Performance

Historical Comparison
NBB
IVVD

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: